Anisole → 3-Chloro-N-[1-(4-fluorophenyl)-2-(piperidin-4-ylmethoxy)-ethyl]-1H-indole-6-carboxamide
反応式
C1(OC)C=CC=CC=1.C(OC([N:16]1[CH2:21][CH2:20][CH:19]([CH2:22][O:23][CH2:24][CH:25]([NH:33][C:34]([C:36]2[CH:44]=[C:43]3[C:39]([C:40]([Cl:45])=[CH:41][NH:42]3)=[CH:38][CH:37]=2)=[O:35])[C:26]2[CH:31]=[CH:30][C:29]([F:32])=[CH:28][CH:27]=2)[CH2:18][CH2:17]1)=O)(C)(C)C>>[Cl:45][C:40]1[C:39]2[C:43](=[CH:44][C:36]([C:34]([NH:33][CH:25]([C:26]3[CH:31]=[CH:30][C:29]([F:32])=[CH:28][CH:27]=3)[CH2:24][O:23][CH2:22][CH:19]3[CH2:20][CH2:21][NH:16][CH2:17][CH2:18]3)=[O:35])=[CH:37][CH:38]=2)[NH:42][CH:41]=1参加物
3
実験手順
Using deprotection method B, but without addition of anisole, 4-{2-[(3-chloro-1H-indole-6-carbonyl)amino]-2-(4-fluorophenyl)ethoxymethyl}piperidine-1-carboxylic acid tert-butyl ester (2.3 g, 4.3 mmol) afforded, after purification (SiO2: 25% isopropyl amine in ethyl acetate), 1.0 g (54%) of the title compound.
後処理
- customafforded
- customafter purification (SiO2: 25% isopropyl amine in ethyl acetate), 1.0 g (54%) of the title compound